中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 37 Issue 6
Jun.  2021
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(6): 1336-1341

Association between the alteration of serum N-glycan profile and the change of glycosyltransferase expression in liver tissue in patients with hepatitis B virus-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.06.024
  • 1.

    Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

  • 2.

    Department of Hepatic Surgery, Liver Disease Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100853, China

  • 3.

    Jiangsu Xiansida Biotechnology Co., Ltd., Nanjing 210000, China

  • Received Date: 2020-11-09
  • Accepted Date: 2020-12-18
  • Published Date: 2021-06-20
    Abstract
  •   Objective  To investigate the potential mechanism of serum N-glycan alterations in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) by measuring serum N-glycan profile and comparing glycosyltransferase gene expression between HCC tissue and adjacent tissue.  Methods  The samples of HCC tissue, adjacent tissue, and normal liver tissue were collected from 34 patients with HBV-related HCC who were admitted to Chinese PLA General Hospital, and serum samples were also collected. Among these 34 patients, 8 were randomly selected and their serum samples were established as HCC experimental group, and the serum samples of 20 healthy adults were established as control group. DNA sequencer-aided fluorophore-assisted carbohydrate electrophoresis was used to analyze serum N-glycan profile in the HCC experimental group and the control group. Quantitative real-time PCR was used to measure the mRNA expression of 8 glycosyltransferase genes (FUT3, FUT4, FUT6, FUT7, FUT8, Gn-TIII, Gn-TIVa, and Gn-TV) in the HCC tissue and adjacent tissue of 34 patients with HBV-related HCC, and Western blot was used to measure the expression of corresponding proteins. The independent samples t-test was used for comparison of continuous data between two groups.  Results  Compared with the control group, the HCC experimental group had a significant increase in the abundance of N-glycan peak9 (NA3Fb) in serum(t=-2.514, P < 0.05). There were significant differences in the mRNA expression of FUT8, Gn-TIVa, and Gn-TV between HCC tissue and adjacent tissue, and the mRNA and protein expression levels of FUT8 and Gn-TV in HCC tissue were significantly higher than those in adjacent tissue (FUT8 mRNA: 1.50±0.34 vs 0.65±0.11, t=-2.354, P=0.022; Gn-TV mRNA: 3.57±0.64 vs 1.33±0.16, t=-3.384, P=0.001; FUT8 protein: 0.70±0.11 vs 0.083±0.017, t=9.555, P=0.001; Gn-TV protein: 1.33±0.19 vs 0.60±0.15, t=5.097, P=0.007). The mRNA expression level of Gn-TIVa in HCC tissue was significantly higher than that in adjacent tissue (2.90±0.47 vs 1.68±0.19, t=-2.403, P=0.019), but there was no significant difference in the protein expression level of Gn-TIVa between HCC tissue and adjacent tissue (0.52±0.24 vs 0.24±0.11, t=1.833, P=0.141). The changes of glycosyltransferase gene expression in HCC tissue were consistent with the alteration of serum N-glycan profile.  Conclusion  Serum N-glycan alterations in patients with HBV-related HCC may be closely associated with the upregulated expression of the glycosyltransferase genes FUT8, Gn-TIVa, and Gn-TV in HCC tissue.

     

    • FullText(HTML)
    • References(19)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [2]
    DRAKE RR. Glycosylation and cancer: Moving glycomics to the forefront[J]. Adv Cancer Res, 2015, 126: 1-10. DOI: 10.1016/bs.acr.2014.12.002.
    [3]
    HÄUSELMANN I, BORSIG L. Altered tumor-cell glycosylation promotes metastasis[J]. Front Oncol, 2014, 4: 28. DOI: 10.3389/fonc.2014.00028.
    [4]
    LIU XE, DESMYTER L, GAO CF, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus[J]. Hepatology, 2007, 46(5): 1426-1435. DOI: 10.1002/hep.21855.
    [5]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [6]
    CAO X, SHANG QH, CHI XL, et al. Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus[J]. World J Gastroenterol, 2020, 26(10): 1067-1079. DOI: 10.3748/wjg.v26.i10.1067.
    [7]
    CHENG L, GAO S, SONG X, et al. Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs[J]. Oncotarget, 2016, 7(38): 61199-61214. DOI: 10.18632/oncotarget.11284.
    [8]
    CHEN C, DIAO D, GUO L, et al. All-trans-retinoic acid modulates ICAM-1 N-glycan composition by influencing GnT-Ⅲ levels and inhibits cell adhesion and trans-endothelial migration[J]. PLoS One, 2012, 7(12): e52975. DOI: 10.1371/journal.pone.0052975.
    [9]
    NIE H, LIU X, ZHANG Y, et al. Specific N-glycans of Hepatocellular Carcinoma Cell Surface and the Abnormal Increase of Core-α-1, 6-fucosylated Triantennary Glycan via N-acetylglucosaminyltransferases-IVa Regulation[J]. Sci Rep, 2015, 5: 16007. DOI: 10.1038/srep16007.
    [10]
    WANG G, LIU J, CAI Y, et al. Loss of Barx1 promotes hepatocellular carcinoma metastasis through up-regulating MGAT5 and MMP9 expression and indicates poor prognosis[J]. Oncotarget, 2017, 8(42): 71867-71880. DOI: 10.18632/oncotarget.18288.
    [11]
    WU X, DAO THI VL, LIU P, et al. Pan-genotype hepatitis E virus replication in stem cell-derived hepatocellular systems[J]. Gastroenterology, 2018, 154(3): 663-674. e7. DOI: 10.1053/j.gastro.2017.10.041.
    [12]
    KIZUKA Y, TANIGUCHI N. Enzymes for N-glycan branching and their genetic and nongenetic regulation in cancer[J]. Biomolecules, 2016, 6(2). DOI: 10.3390/biom6020025.
    [13]
    FANG M, ZHAO YP, ZHOU FG, et al. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma[J]. Int J Cancer, 2010, 127(1): 148-159. DOI: 10.1002/ijc.25030.
    [14]
    CUI J, HUANG W, WU B, et al. N-glycosylation by N-acetylglucosaminyltransferase V enhances the interaction of CD147/basigin with integrin β1 and promotes HCC metastasis[J]. J Pathol, 2018, 245(1): 41-52. DOI: 10.1002/path.5054.
    [15]
    FAN J, WANG S, YU S, et al. N-acetylglucosaminyltransferase IVa regulates metastatic potential of mouse hepatocarcinoma cells through glycosylation of CD147[J]. Glycoconj J, 2012, 29(5-6): 323-334. DOI: 10.1007/s10719-012-9414-1.
    [16]
    ZHAO Y, NAKAGAWA T, ITOH S, et al. N-acetylglucosaminyltransferase Ⅲ antagonizes the effect of N-acetylglucosaminyltransferase V on alpha3beta1 integrin-mediated cell migration[J]. J Biol Chem, 2006, 281(43): 32122-32130. DOI: 10.1074/jbc.M607274200.
    [17]
    ZHAO Y, ITOH S, WANG X, et al. Deletion of core fucosylation on alpha3beta1 integrin down-regulates its functions[J]. J Biol Chem, 2006, 281(50): 38343-38350. DOI: 10.1074/jbc.M608764200.
    [18]
    DEBRUYNE EN, DELANGHE JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications[J]. Clin Chim Acta, 2008, 395(1-2): 19-26. DOI: 10.1016/j.cca.2008.05.010.
    [19]
    KEELEY TS, YANG S, LAU E. The diverse contributions of fucose linkages in cancer[J]. Cancers (Basel), 2019, 11(9). DOI: 10.3390/cancers11091241.
    • Relative Articles

  • Relative Articles

    [1]Xin DAI, Hanlin LIU, Long CHENG, Zhulin LUO, Tao WANG. Association of programmed death-1 and programmed death-ligand 1 with the prognosis and clinical features of patients with hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1577-1583. doi: 10.3969/j.issn.1001-5256.2022.07.022
    [2]Pan LIU, Liang HAO, Yu CHENG, Beibei YANG, Yong WEI, Zhenhong XIA, Shoujun YU. Advances in the application of ultrasound in the diagnosis and treatment of acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(12): 2873-2876. doi: 10.3969/j.issn.1001-5256.2022.12.037
    [3]Xiangliu OUYANG, Yunxia HAN, Lichun ZHENG, Yingchun ZHAO, Xinyu SHEN, Wenjun ZHANG, Yanbin WANG. Ultrasound findings and contrast-enhanced ultrasound findings of mass-type autoimmune pancreatitis versus pancreatic ductal adenocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(6): 1351-1355. doi: 10.3969/j.issn.1001-5256.2022.06.025
    [4]Quan ZHOU, Lihui YANG, Fangqing JIANG. Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1836-1840. doi: 10.3969/j.issn.1001-5256.2021.08.018
    [5]Minjun LI, Zhujian DENG, Haotian LIU, Yuxian TENG, Rongrui HUO, Xiumei LIANG, Bangde XIANG, Lequn LI, Jianhong ZHONG. Clinical effect of re-hepatic resection versus radiofrequency ablation in treatment of recurrent hepatocellular carcinoma in Asia: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1103-1109. doi: 10.3969/j.issn.1001-5256.2021.05.025
    [6]Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
    [7]Ying LIU, Benjian GAO, Xiaoli YANG, Cheng FANG, Song SU, Bo LI. Effect of hemihepatic vascular exclusion versus total hepatic vascular exclusion in hepatectomy for primary liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(1): 73-78. doi: 10.3969/j.issn.1001-5256.2021.01.015
    [8]Shun ZHU, Zhiguo LI, Shuo LI, Xu CAO, Xiaobin LI, Xiaoke LI, Yongan YE. Effect of aspirin on the incidence rate of liver cancer in patients with viral hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1097-1102. doi: 10.3969/j.issn.1001-5256.2021.05.024
    [9]Sun DongXue, Yang Zhu, Long FengXi, Wei XianMan, Tang DongXin. Efficacy and safety of Kanglaite injection combined with transarterial chemoembolization in treatment of advanced liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 363-368. doi: 10.3969/j.issn.1001-5256.2020.02.026
    [10]Qian Le, Ying Li. Selection of second-line drugs for adult autoimmune hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2015-2020. doi: 10.3969/j.issn.1001-5256.2020.09.021
    [11]Zhou ZiDong, Li RenLi, Chen Kai, Zhang WenCheng, Xia ShiHai. Clinical effect of epidermal growth factor receptor-targeted agents in treatment of advanced pancreatic cancer:A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(5): 1097-1103. doi: 10.3969/j.issn.1001-5256.2020.05.029
    [12]Zi Li, Chen Kai, Liu GuangLin, Li RenLi, Xu Wei. Clinical effect of gemcitabine combined with high-intensity focused ultrasound in treatment of advanced pancreatic cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(1): 153-157. doi: 10.3969/j.issn.1001-5256.2020.01.034
    [13]Li Dong, Luo TianYang, Ran YaWei. Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2214-2219. doi: 10.3969/j.issn.1001-5256.2019.10.017
    [14]Wang YiBin, Liao JinTang, Xie LuLu, Qi WenJun, Chen LuYang, Li YueYi. Predictive value of preoperative ultrasound examination for factors associated with early postoperative recurrence of hepatocellular carcinoma after surgical resection [J]. Journal of Clinical Hepatology, 2015, 31(12): 2061-2065. doi: 10.3969/j.issn.1001-5256.2015.12.018
    [15]Liu LingFeng, Lu HaiYing, Yu YanYan, Wu ChiHong, Tian XiuLan. A comparative study of FibroScan and B ultrasound in diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(10): 1045-1049. doi: 10.3969/j.issn.1001-5256.2014.10.018
    [16]Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the management of pancreatic cancer (2014)[J]. Journal of Clinical Hepatology, 2014, 30(12): 1240-1245. doi: 10.3969/j.issn.1001-5256.2014.12.003
    [17]Li ChunSheng, Ni CanRong. Expression of S100A4 and E-cadherin in pancreatic carcinoma and their relationship study[J]. Journal of Clinical Hepatology, 2006, 22(3): 207-208.
    [18]Ren Ben, Song JiangBo, Zhang FenQin, Si HongXia, Gao XuanXia. Stereotactic radiotherapy in 206 patients with pancreatic carcinoma[J]. Journal of Clinical Hepatology, 2006, 22(1): 52-53.
    [20]Yuan ZhangJi, Yang Lei, Yao Cheng, Wang GuanJun. Observation of high intensity focused ultrasound treating 40 cases of cancer of pancreas[J]. Journal of Clinical Hepatology, 2003, 19(3): 145-146.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(37)

    1. 李容容，苟悦，刘宁宁，陈日润，孙鑫，刘成海. 基于临床数据挖掘的中药对抗肿瘤药物相关肝损伤的影响及用药规律探讨. 时珍国医国药. 2024(01): 243-247 .
    2. 张倩茹，卢颖，张婉婷，杨艳. 某院急性白血病患者药源性肝损伤临床治疗的回顾性分析. 遵义医科大学学报. 2024(04): 401-407 .
    3. 中华医学会，中华医学会杂志社，中华医学会肝病分会药物性肝病学组，中华医学会全科医学分会，中华医学会《中华全科医师杂志》编辑委员会，中国医药生物技术协会药物性肝损伤防治技术专业委员会，中国初级卫生保健基金会药物肝脏安全性专业委员会，中国药物性肝损伤基层诊疗与管理指南制定专家组. 中国药物性肝损伤基层诊疗与管理指南(2024年). 中华全科医师杂志. 2024(08): 813-830 .
    4. 郑晖，孙蓉. 药物联合应用对中草药相关肝损伤的影响. 临床肝胆病杂志. 2024(08): 1519-1524 . 本站查看
    5. 李容容，李盟，苟悦，罗琼，吕桦，孙鑫，刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析. 中国药物警戒. 2023(05): 505-510 .
    6. 中国医药生物技术协会药物性肝损伤防治技术专业委员会，中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版). 中华肝脏病杂志. 2023(04): 355-384 .
    7. 程诗思，杨成明，曾安津. 荆州地区结核病专科医院抗结核药物不良反应分析. 临床合理用药. 2023(22): 147-150 .
    8. 江程，李春晓，杨玉晴，郭静. 热毒宁注射液上市后临床安全性文献研究. 中国药事. 2023(11): 1252-1265 .
    9. 王双双，熊清芳，胡一帆，陈妙洋，杨永峰. 药物性肝损伤的临床与病理特点分析. 肝脏. 2023(11): 1280-1284 .
    10. 孟尧，张萌萌，郭甜甜，赵新颜. 《中国药物性肝损伤诊治指南（2023年版）》更新要点解读. 中国肝脏病杂志(电子版). 2023(04): 1-5 .
    11. 马世武，刘成海，刘晓琰，苏明华，李东良，李异玲，陈公英，陈军，陈金军，茅益民，赵景民，郭晓燕，唐洁婷，诸葛宇征，谢青，谢雯，赖荣陶，蔡大川，蔡庆贤. 中国药物性肝损伤诊治指南（2023年版）. 胃肠病学. 2023(07): 397-431 .
    12. 孙晓楠，吕萌，程国亭. 药物性肝损伤139例回顾性分析. 中南医学科学杂志. 2022(03): 391-394 .
    13. 李娜. 肺癌患者化疗后药物性肝损伤的临床特点. 中国医药指南. 2022(16): 22-25 .
    14. 劳明珠. 异甘草酸镁治疗抗肿瘤药物引起的急性药物性肝损伤临床效果和安全性. 临床合理用药杂志. 2022(17): 84-87 .
    15. 马万龙，焦运，张旭，丁向春，张平，欧阳花，王梦甜，张乐，徐灵博，杨安宁，姜怡邓. 血清IL-6在人工肝治疗药物性肝损伤预后评估中的价值. 宁夏医科大学学报. 2022(06): 622-629 .
    16. 沈婷婷，李光耀，罗琼，李盟，孙鑫，陶艳艳，周祖山，刘成海. 类风湿性关节炎患者应用雷公藤制剂及合并用药所致药物性肝损伤的临床特征分析. 临床肝胆病杂志. 2022(09): 2067-2072 . 本站查看
    17. 马世武，刘成海，刘晓琰，苏明华，李东良，李异玲，陈公英，陈军，陈金军，茅益民，赵景民，郭晓燕，唐洁婷，诸葛宇征，谢青，谢雯，赖荣陶，蔡大川，蔡庆贤. 中国药物性肝损伤诊治指南（2023年版）. 胃肠病学. 2022(06): 341-375 .
    18. 汪涛，王学伟，蒋元烨，曹勤，季光. 162例药物性肝损伤患者分析. 肝脏. 2021(03): 243-246 .
    19. 王艳，王昱，王岚，田秋菊，杨瑞园，李柯鑫，刘立伟，王晓明，王宇，欧晓娟，贾继东，赵新颜. 中草药与西药致药物性肝损伤的临床特征及其预后的对比研究. 肝脏. 2021(04): 364-369 .
    20. 杨焕芝，李兴德，陈学平，张仲安，钱彦华，蒋潇，徐艳琼，宋沧桑. 93例药物性肝损伤患者临床特征分析. 中国药业. 2021(15): 122-125 .
    21. 何婷婷，王丽苹，任璐彤，崔延飞，柏兆方，郭玉明，宫嫚，王睿林. 中西药肝损伤临床及病理特征分析. 肝脏. 2021(09): 962-967 .
    22. 刘秀兰，李为，郭敏，杜金凤，刘东，李娟. 药物性肝损伤相关医疗损害案例分析. 药物流行病学杂志. 2021(11): 729-734 .
    23. 陈凯霞，赵广玉，印登阳，陈宏俊，黄继勋. 三种保肝药治疗化疗引起的DILI的药物经济学评价. 中国实用医药. 2021(35): 188-191 .
    24. 罗琼，朱哿瑞，顾宏图，刘坤，陈高峰，邢枫，陶艳艳，刘成海. 50例中草药与西药致药物性肝损伤患者的肝组织病理学特点比较. 临床肝胆病杂志. 2020(03): 596-601 . 本站查看
    25. 蔡春梅. 妊娠早期肝功能异常60例的病因分析及干预. 中国城乡企业卫生. 2020(06): 100-102 .
    26. 周力. 中西药所致药物性肝损伤临床及病理特点研究. 临床医药文献电子杂志. 2020(39): 56 .
    27. 纪童童，陆海英，谭宁，于岩岩，徐小元. 急、慢性药物性肝损伤临床特征的对比分析. 临床肝胆病杂志. 2020(07): 1556-1561 . 本站查看
    28. 何文昌，张克恭，赵凡惠，郭芮杉，高禄化，黄长形，王临旭. 290例药物性肝损伤患者临床特征分析. 实用肝脏病杂志. 2020(04): 540-543 .
    29. 李梁，陶应敏，张学敏，谢娟，陈园. 药物性肝损伤患者外周血清HIF1α和COX-2定量检测的临床价值. 肝脏. 2020(08): 848-852 .
    30. 李卉，张宏亮，杨天燕，黄振光，刘滔滔，韦芳. 我院125例抗结核药物不良反应报告分析. 中国医药导报. 2020(29): 151-154 .
    31. 姜正艳，郑亮. 异甘草酸镁治疗药物性肝损伤临床疗效观察. 世界最新医学信息文摘. 2019(07): 123 .
    32. 张惠娟，史祖宣，赵兰芳，高天慧，李健. 56例抗肿瘤药物致肝损伤临床特点分析. 临床肝胆病杂志. 2019(03): 574-578 . 本站查看
    33. 梁栋，董晓锋，张燕，朱晓红，王建斌，刘妲妲，柳伟伟，方圆，王全楚. 98例药物性肝损伤的临床特点及诊疗体会. 肝脏. 2019(04): 389-391 .
    34. 黄波，张炜. 喜炎平注射液联合还原型谷胱甘肽治疗重症烧伤后急性肝功能损伤临床研究. 创伤与急危重病医学. 2019(03): 156-159 .
    35. 郭立杰，张海丛，叶立红，王超，杜婧，伍彦辉. 中西药所致药物性肝损伤临床及病理特点分析. 临床误诊误治. 2019(08): 28-33 .
    36. 吴宇宇，袁苏榆，孙四珍，王岁晶，丁洋. 药物性肝损伤诊断治疗进展概述. 药物流行病学杂志. 2018(08): 550-555 .
    37. 王建青，叶珺，郜玉峰，杨利琦. 106例药物性肝损伤患者用药回顾性调查. 中国医院药学杂志. 2018(18): 1967-1970 .

    Other cited types(11)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 2.7 %FULLTEXT: 2.7 %META: 94.1 %META: 94.1 %PDF: 3.1 %PDF: 3.1 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 6.3 %其他: 6.3 %其他: 0.6 %其他: 0.6 %China: 0.6 %China: 0.6 %Congo: 0.1 %Congo: 0.1 %Croatia (LOCAL Name: Hrvatska): 0.3 %Croatia (LOCAL Name: Hrvatska): 0.3 %Falls Church: 0.1 %Falls Church: 0.1 %Hong Kong, China: 0.1 %Hong Kong, China: 0.1 %India: 0.3 %India: 0.3 %Seattle: 0.2 %Seattle: 0.2 %United States: 0.6 %United States: 0.6 %[]: 0.6 %[]: 0.6 %上海: 4.4 %上海: 4.4 %东莞: 0.1 %东莞: 0.1 %丽水: 0.6 %丽水: 0.6 %佛山: 0.1 %佛山: 0.1 %六安: 0.1 %六安: 0.1 %北京: 5.1 %北京: 5.1 %南京: 3.0 %南京: 3.0 %南宁: 0.1 %南宁: 0.1 %南阳: 0.1 %南阳: 0.1 %厦门: 0.1 %厦门: 0.1 %台州: 1.5 %台州: 1.5 %吉林: 0.4 %吉林: 0.4 %吉隆坡: 0.1 %吉隆坡: 0.1 %呼和浩特: 0.1 %呼和浩特: 0.1 %哈尔滨: 0.2 %哈尔滨: 0.2 %哥伦布: 0.1 %哥伦布: 0.1 %嘉兴: 0.1 %嘉兴: 0.1 %大连: 0.4 %大连: 0.4 %天津: 0.2 %天津: 0.2 %太原: 0.1 %太原: 0.1 %孝感: 0.1 %孝感: 0.1 %宁波: 0.1 %宁波: 0.1 %常德: 0.1 %常德: 0.1 %广州: 1.2 %广州: 1.2 %开封: 0.2 %开封: 0.2 %张家口: 1.8 %张家口: 1.8 %悉尼: 0.1 %悉尼: 0.1 %成都: 0.5 %成都: 0.5 %晋城: 0.1 %晋城: 0.1 %杭州: 1.0 %杭州: 1.0 %武汉: 0.4 %武汉: 0.4 %沈阳: 0.2 %沈阳: 0.2 %海得拉巴: 0.1 %海得拉巴: 0.1 %淮南: 0.1 %淮南: 0.1 %湖州: 1.1 %湖州: 1.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.2 %漯河: 0.2 %福州: 0.4 %福州: 0.4 %约翰内斯堡: 0.3 %约翰内斯堡: 0.3 %绍兴: 0.1 %绍兴: 0.1 %芒廷维尤: 30.8 %芒廷维尤: 30.8 %芝加哥: 0.4 %芝加哥: 0.4 %苏州: 0.2 %苏州: 0.2 %莫斯科: 1.3 %莫斯科: 1.3 %萨格勒布: 0.1 %萨格勒布: 0.1 %衡阳: 0.1 %衡阳: 0.1 %衢州: 0.6 %衢州: 0.6 %西宁: 25.8 %西宁: 25.8 %西安: 0.8 %西安: 0.8 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.2 %赤峰: 0.2 %运城: 1.0 %运城: 1.0 %郑州: 0.5 %郑州: 0.5 %金华: 0.1 %金华: 0.1 %长春: 2.2 %长春: 2.2 %长沙: 0.6 %长沙: 0.6 %长治: 0.1 %长治: 0.1 %青岛: 0.2 %青岛: 0.2 %驻马店: 0.1 %驻马店: 0.1 %高雄: 0.1 %高雄: 0.1 %黄冈: 0.1 %黄冈: 0.1 %其他其他ChinaCongoCroatia (LOCAL Name: Hrvatska)Falls ChurchHong Kong, ChinaIndiaSeattleUnited States[]上海东莞丽水佛山六安北京南京南宁南阳厦门台州吉林吉隆坡呼和浩特哈尔滨哥伦布嘉兴大连天津太原孝感宁波常德广州开封张家口悉尼成都晋城杭州武汉沈阳海得拉巴淮南湖州湘潭漯河福州约翰内斯堡绍兴芒廷维尤芝加哥苏州莫斯科萨格勒布衡阳衢州西宁西安贵阳赤峰运城郑州金华长春长沙长治青岛驻马店高雄黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (703) PDF downloads(44) Cited by(48)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1352]YesterdayPV[2703]TodayIP[1511]TodayPV[2563]Online[42]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return